Trial
NCT01732926
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
Phase IIITERMINATEDSAFETYConfidence: HIGH
Sponsor
Gilead Sciences
Collaborators
—
Condition
Indolent Non-Hodgkin's Lymphomas
Intervention
Idelalisib
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-11-16